Copyright
©The Author(s) 2015.
World J Gastroenterol. May 14, 2015; 21(18): 5654-5662
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5654
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5654
Table 5 Patients’ survival according to modified Barcelona Clinic Liver Cancer staging system
| 1-yr survival | 2-yr survival | 3-yr survival | Median survival (mo) | P value | ||
| BCLC A | No ascites, AFP < 200 ng/mL (n = 280) | 93% | 77% | 70% | 39 | < 0.001 |
| Ascites or AFP ≥ 200 ng/mL (n = 175) | 84% | 59% | 36% | 30 | ||
| Ascites, AFP ≥ 200 ng/mL (n = 41) | 83% | 23% | 23% | 19 | ||
| BCLC B | No ascites, AFP < 200 ng/mL (n = 237) | 77% | 40% | 21% | 22 | |
| Ascites or AFP ≥ 200 ng/mL (n = 261) | 67% | 27% | 15% | 18 | ||
| Ascites, AFP ≥ 200 ng/mL (n = 66) | 46% | 15% | 7% | 12 | ||
- Citation: Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World J Gastroenterol 2015; 21(18): 5654-5662
- URL: https://www.wjgnet.com/1007-9327/full/v21/i18/5654.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i18.5654